Literature DB >> 9796049

Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin.

M Hotomi1, T Saito, N Yamanaka.   

Abstract

Nontypeable Haemophilus influenzae (NTHi) is one of the leading pathogens in otitis media. Studies of vaccines against NTHi have focused on outer membrane proteins (OMPs). One outer membrane protein P6 is highly conserved among strains and is an attractive candidate for a subunit bacterial vaccine. In this study, mucosal immunity induced by intranasal immunization with P6 and cholera toxin (CT) was investigated in a mouse model. Intranasal immunization with P6 and CT evoked a good mucosal IgA as well as a systemic IgG response against P6. On the other hand, intranasal immunization with P6 alone induced a weak mucosal IgA response. Enzyme linked immunospot assay detected anti-P6 specific antibody producing cells in the nasopharyngeal mucosa of immunized mice. The protective response of intranasal immunization was demonstrated by enhancement of nasopharyngeal clearance of NTHi and inhibition of adherence of NTHi to cultured human epithelial cells. Based on these results, intranasal immunization with P6 and CT may be an effective approach to protect human from H. influenzae infections in the upper respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796049     DOI: 10.1016/s0264-410x(98)00122-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.

Authors:  L O Bakaletz; B J Kennedy; L A Novotny; G Duquesne; J Cohen; Y Lobet
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

4.  Construction of a mutant and characterization of the role of the vaccine antigen P6 in outer membrane integrity of nontypeable Haemophilus influenzae.

Authors:  Timothy F Murphy; Charmaine Kirkham; Alan J Lesse
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

5.  Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization.

Authors:  S Kodama; S Suenaga; T Hirano; M Suzuki; G Mogi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2007-01-26       Impact factor: 3.641

Review 7.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 8.  Mouse models for human otitis media.

Authors:  Dennis R Trune; Qing Yin Zheng
Journal:  Brain Res       Date:  2009-03-06       Impact factor: 3.252

9.  Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

10.  Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein.

Authors:  Yuka Nomura; Yusuke Abe; Yoshiya Ishida; Hiroya Kobayashi; Yasuaki Harabuchi
Journal:  J Clin Immunol       Date:  2008-04-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.